http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019054966-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3b8c452cb087bd86b9d719dd4ffb0b2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3f52cbf7368ddf19e4e70266477ab00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb36aaa638a032cc70ae962e1dc0b732 |
| publicationDate | 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019054966-A2 |
| titleOfInvention | CHEMOTHERAPEUTIC DRUG COMPOSITION |
| abstract | The present invention relates to a chemotherapeutic drug composition, which is prepared by combining éverolimus, one of the drugs used in the treatment of metastatic renal cell carcinoma (RCC) which now accounts for 2 to 3% of malignant tumors, with the Bcl-2 anti-apoptotic inhibitor ABT-737 for the treatment of CCR tumors that have developed drug resistance. The success of the treatment with the present composition has been studied for the treatment of CRC in the context of the invention. In this regard, the effect of the drug composition of éverolimus and ABT-737 on cell survival and cell death in ERV-resistant CRC cell lines overexpressing BcI-2 protein has been demonstrated. by in vitro and in vivo experiments and the mechanism of effect of the drug composition on the CRC was examined from a molecular point of view. The invention comprises the administration of Navitoclax (ABT-263), an orally available analogue of ABT-737, and other Bcl-2 inhibitors alone or in combination with everolimus, which is administered once daily at a dose of 10 mg, for use in the treatment of ERF-resistant CRC. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285159-B2 |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 233.